Howe & Rusling Inc. Has $5.08 Million Holdings in Celgene Co. (CELG)
Howe & Rusling Inc. raised its holdings in shares of Celgene Co. (NASDAQ:CELG) by 15.6% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 34,859 shares of the biopharmaceutical company’s stock after purchasing an additional 4,713 shares during the period. Howe & Rusling Inc.’s holdings in Celgene were worth $5,083,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Neuberger Berman Group LLC increased its position in shares of Celgene by 4.0% during the first quarter. Neuberger Berman Group LLC now owns 1,844,837 shares of the biopharmaceutical company’s stock valued at $229,553,000 after acquiring an additional 71,729 shares in the last quarter. Grisanti Capital Management LLC bought a new stake in shares of Celgene during the second quarter valued at approximately $3,616,000. Lincoln Capital Corp increased its position in shares of Celgene by 0.6% during the second quarter. Lincoln Capital Corp now owns 30,580 shares of the biopharmaceutical company’s stock valued at $3,971,000 after acquiring an additional 185 shares in the last quarter. RiverPoint Capital Management LLC increased its position in shares of Celgene by 3.1% during the second quarter. RiverPoint Capital Management LLC now owns 121,654 shares of the biopharmaceutical company’s stock valued at $15,799,000 after acquiring an additional 3,680 shares in the last quarter. Finally, Russell Investments Group Ltd. increased its position in shares of Celgene by 9.2% during the second quarter. Russell Investments Group Ltd. now owns 641,697 shares of the biopharmaceutical company’s stock valued at $83,344,000 after acquiring an additional 54,210 shares in the last quarter. 80.16% of the stock is owned by institutional investors and hedge funds.
Several brokerages recently weighed in on CELG. Vetr downgraded shares of Celgene from a “strong-buy” rating to a “buy” rating and set a $121.72 price target for the company. in a research report on Monday. Oppenheimer set a $166.00 price target on shares of Celgene and gave the company a “buy” rating in a research report on Thursday. Leerink Swann reissued a “buy” rating and set a $120.00 price target on shares of Celgene in a research report on Wednesday, December 13th. Credit Suisse Group set a $128.00 price target on shares of Celgene and gave the company a “buy” rating in a research report on Tuesday, December 12th. Finally, Deutsche Bank began coverage on shares of Celgene in a research report on Tuesday, December 12th. They set a “hold” rating and a $114.00 price target for the company. One research analyst has rated the stock with a sell rating, twelve have assigned a hold rating, twenty-one have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $136.21.
In other news, insider Terrie Curran sold 1,727 shares of Celgene stock in a transaction on Monday, September 25th. The shares were sold at an average price of $143.89, for a total transaction of $248,498.03. Following the transaction, the insider now owns 3,925 shares in the company, valued at approximately $564,768.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 0.95% of the company’s stock.
Shares of Celgene Co. (NASDAQ CELG) opened at $109.41 on Monday. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.65 and a quick ratio of 3.52. Celgene Co. has a 1 year low of $94.55 and a 1 year high of $147.17. The company has a market cap of $86,140.36, a P/E ratio of 17.10, a price-to-earnings-growth ratio of 0.84 and a beta of 1.78.
Celgene (NASDAQ:CELG) last posted its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 EPS for the quarter, topping analysts’ consensus estimates of $1.87 by $0.04. The business had revenue of $3.29 billion during the quarter, compared to the consensus estimate of $3.42 billion. Celgene had a net margin of 27.36% and a return on equity of 63.80%. The firm’s revenue was up 10.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.58 EPS. equities analysts expect that Celgene Co. will post 6.68 earnings per share for the current year.
WARNING: This story was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this story on another website, it was stolen and republished in violation of United States & international copyright and trademark law. The legal version of this story can be read at https://www.watchlistnews.com/howe-rusling-inc-has-5-08-million-holdings-in-celgene-co-celg/1770564.html.
Celgene Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with Analyst Ratings Network's FREE daily email newsletter.